AMRI acquires Gadea Pharmaceutical Group

Wednesday, July 22, 2015

Albany Molecular Research (AMRI), a global contract research and manufacturing organization based in Albany, N.Y., has acquired all the outstanding shares of Gadea Pharmaceutical Group, a privately held company located in Valladolid, Spain, specializing in technically complex active pharmaceutical ingredients (APIs) and finished drug product. The purchase price was $174 million, including the issuance of 2.2 million shares of common stock to Gadea’s owners, valued at $43.8 million, with the balance paid in cash and through the assumption of existing debt.

[Read More]

AMRI, PerkinElmer collaborate on Buffalo Medical Hub

Friday, June 19, 2015

Global CRO Albany Molecular Research (AMRI) and CRO PerkinElmer are collaborating in connection with the opening of AMRI’s drug discovery center as part of the new Buffalo Medical Innovation and Commercialization Hub (BMIC). Co-located on the Buffalo Niagara Medical Campus and part of the larger commitment by the State of New York with SUNY Polytechnic Institute, the Hub will accelerate drug discovery and innovation, and ultimately support the creation of more than 250 high tech jobs.

[Read More]

CPhI Pharma Awards 2015 open with five new categories

Monday, June 15, 2015

CPhI Worldwide, organized by UBM EMEAhas opened the annual CPhI Pharma Awards for 2015, with five new categories covering the entire pharmaceutical supply chain. Now in their 12th consecutive year, the awards will honor companies and individuals driving the pharma industry forward through innovations, new approaches, technologies and strategies.  

[Read More]

AMRI, HarkerBIO collaborate

Friday, June 5, 2015

Albany Molecular Research (AMRI), a CRO based in Albany, N.Y., has signed a collaborative agreement with Buffalo, N.Y.-based biotechnology company HarkerBIO to co-market their structure-based drug discovery services to global pharmaceutical and biotechnology clients. AMRI gains access to HarkerBIO’s differentiated high-resolution, structure-determination experience and capabilities. HarkerBIO’s customers will be able to access and benefit from AMRI’s global capabilities, including their integrated drug discovery platforms and solutions.

[Read More]

AMRI to shutter U.K. facility, lay off 62 workers

Monday, April 6, 2015

Albany Molecular Research (AMRI), a global contract research and manufacturing organization, has decided to close its Holywell, U.K., facility, which provides chemical development services and small- and large-scale manufacturing services of active pharmaceutical ingredients (API) and intermediates.

[Read More]

AMRI hires VP of International Sales

Thursday, March 5, 2015

Albany Molecular Research (AMRI), a global CRO based in Albany, N.Y., has hired Michael Pettersson to fill the newly created position of vice president of International Sales, effective immediately. He reports to Christopher Conway, senior vice president of Global Sales and Marketing.

[Read More]

AMRI hires Jimmy Wang as chief information officer

Wednesday, February 11, 2015

Albany Molecular Research (AMRI), a global contract research and manufacturing organization, has hired Jimmy Wang, Ph.D., to fill the newly created position of chief information officer, effective immediately. He replaces Carl Neumann, senior director, information technology, who retires this month.

[Read More]

AMRI announces CFO transition

Friday, January 16, 2015

Michael M. Nolan, senior vice president and chief financial officer, will be departing Albany Molecular Research (AMRI), a global contract research and manufacturing organization. Nolan will remain with AMRI through February 2015 to support an orderly transition. Felicia Ladin will join the company in the same role, effective Feb. 4, 2015.

[Read More]

AMRI to acquire Aptuit drug development, aseptic manufacturing businesses

Friday, January 9, 2015

Albany Molecular Research (AMRI), a global contract research and manufacturing organization, has acquired the outstanding equity interests of Aptuit‘s Glasgow, U.K., business and has entered into a definitive agreement to acquire Aptuit’s SSCI/West Lafayette, Ind., business, for a total of $60 million, expanding AMRI’s drug product development and aseptic clinical manufacturing capabilities.

[Read More]

AMRI’s expands discovery biology offerings

Monday, September 8, 2014

Albany Molecular Research (AMRI), a New York-based global CRO, has expanded into the protein market, with an initial focus on protein expression and purification. The global revenue of the total proteomics market is anticipated to grow at a compound annual growth rate of about 4.1% to about $9.2 billion by 2018.

[Read More]